Oritinib is an investigational new drug currently under investigation for its potential use in cancer treatment. As a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, oritinib targets specific enzymes involved in the signaling pathways that regulate cell division and survival, which are often dysregulated in cancer cells.
References